Trial Profile
A pharmacokinetic study on formulation of adalimumab biosimilar (CHS-1420)
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 20 Mar 2017
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary)
- Indications Plaque psoriasis
- Focus Pharmacokinetics
- 20 Mar 2017 New trial record
- 13 Mar 2017 According to a Coherus Biosciences media release, company plans to initiate this study in the second-half of 2017.